Ozempic Dosing Schedule Explained:
From 0.25 mg to 2.4 mg

Semaglutide comes in two branded versions with different dosing:

Ozempic (for type 2 diabetes):

• Weeks 1–4: 0.25 mg weekly (initiation dose)
• Weeks 5–8: 0.5 mg weekly
• Week 9+: 1.0 mg weekly
• Optional: 2.0 mg weekly (if additional glycemic control is needed)

Wegovy (for weight management):

• Weeks 1–4: 0.25 mg weekly
• Weeks 5–8: 0.5 mg weekly
• Weeks 9–12: 1.0 mg weekly
• Weeks 13–16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance dose)

The key difference: Wegovy's schedule goes higher (2.4 mg vs 2.0 mg) and includes the 1.7 mg intermediate step. The STEP clinical trials used the 2.4 mg dose — this is where the headline "15% average weight loss" comes from.

GLP-1 receptor agonists slow gastric emptying, alter gut motility, and change how your brain processes hunger and satiety signals. Your body needs time to recalibrate.

• GI adaptation — nausea, the most common side effect, is dose-dependent and introduction-dependent. In the STEP trials, nausea peaked during the first few weeks of each dose increase, then subsided. Slow titration gives your gut time to adjust before adding more medication.
• Receptor sensitivity — GLP-1 receptors in the brain and gut need time to downregulate their sensitivity to the new baseline stimulation. Jumping to a high dose overwhelms these receptors and produces stronger (and more unpleasant) effects.
• Compliance and retention — in the SUSTAIN trials, the slow-titration group had significantly higher retention at 68 weeks than patients who experienced severe early side effects. Tolerability predicts long-term success.

The prescribers who produce the best patient outcomes are often the ones who are most patient with titration — sometimes holding a dose for 6–8 weeks instead of 4 if side effects haven't fully resolved.

0.25 mg — The Introduction

• Appetite suppression: mild. Many users report a subtle reduction in "food noise" — the constant mental chatter about eating.
• Weight loss: minimal (0–3 lbs over 4 weeks), mostly from naturally eating less.
• Side effects: mild nausea in ~40% of users, usually in the first 24–48 hours after injection. Fatigue and injection site reactions are common.
• Purpose: let your body adapt. This dose is not expected to produce clinically meaningful weight loss.

0.5 mg — First Therapeutic Dose

• Appetite suppression: noticeable. Most users feel the medication "working" at this level. Portions shrink naturally.
• Weight loss: 4–8 lbs from baseline by the end of the 0.5 mg phase (cumulative, including time on 0.25 mg).
• Side effects: nausea may return briefly after the dose increase (3–7 days). Constipation often appears at this dose as gastric emptying slows further. Fiber and hydration are essential.
• This is where many diabetes patients stay long-term if glycemic targets are met.

1.0 mg — The Standard Dose

• Appetite suppression: strong. Most users report being unable to finish meals they previously ate easily.
• Weight loss: 8–15 lbs from baseline by month 3–4 (cumulative). This is where the weight loss curve steepens.
• Side effects: GI symptoms are typically manageable by this point for most users. New side effects are uncommon — this dose is an amplification of what you've already experienced.
• For Ozempic users (diabetes indication), this is the standard maintenance dose.

1.7 mg — Wegovy Intermediate

• Only available in the Wegovy formulation. This is a bridge dose between 1.0 mg and 2.4 mg.
• Appetite suppression: very strong. Some users struggle to eat enough at this level and need to prioritize calorie and protein intake actively.
• Weight loss: accelerates further. Cumulative loss from baseline typically 15–25 lbs by this point.
• Side effects: generally well-tolerated if you handled 1.0 mg without significant issues. Some users report increased fatigue from lower caloric intake rather than the medication itself.

2.0–2.4 mg — Maximum Dose

• Appetite suppression: maximal. This is the ceiling of what the medication can do for hunger reduction.
• Weight loss: the STEP 1 trial's 14.9% average came from 2.4 mg maintained for over a year. Individual results vary enormously — some users lose 25%+ of body weight, others plateau around 10%.
• Side effects: most GI symptoms have resolved by this point. The most persistent complaints are mild nausea after large or fatty meals, sulfur burps, and constipation. Serious GI events (pancreatitis, gallbladder issues) are rare but monitored.

Side effects correlate with dose increases more than with absolute dose level. The STEP and SUSTAIN trials consistently showed:

• Nausea: Most common in the first 1–2 weeks of each dose increase. Reported by 44% of users overall (STEP 1), but most episodes were transient and mild-to-moderate. Severe nausea requiring medical intervention: less than 3%.
• Constipation: Increases with dose. Reported by 24% at the therapeutic dose. Responds well to fiber supplementation (psyllium husk), magnesium citrate, and increased water intake.
• Diarrhea: 32% overall, often alternating with constipation. More common in the first 2 months.
• Vomiting: 25% overall, but strongly correlated with overeating on the medication. Eating smaller meals is the primary prevention.
• Discontinuation due to GI events: 4.5% in STEP 1. Meaning 95.5% of participants tolerated the medication through the full trial.

The published titration schedule is a guideline, not a mandate. Experienced prescribers modify it regularly:

• Extending a dose — if nausea or GI symptoms haven't resolved after 4 weeks, staying at the current dose for 6–8 weeks before increasing is common and appropriate. There's no penalty for going slow.
• Holding at a lower dose — some patients respond well at 0.5 mg or 1.0 mg and don't need higher doses. If weight loss is progressing and side effects are minimal, dose escalation isn't automatic.
• Reducing the dose — if side effects at a higher dose are intolerable, stepping back down for 4–8 weeks and then reattempting the increase is standard practice. This isn't failure — it's personalization.
• Skipping the 0.25 mg step — rarely recommended, but some prescribers start patients directly at 0.5 mg if they've previously tolerated other GLP-1 medications or if the 0.25 mg pen isn't available. Higher risk of initial GI symptoms.

"Maintenance dose" is the dose at which you stay long-term — either the maximum dose (2.4 mg for Wegovy, 2.0 mg for Ozempic) or the dose where you've achieved adequate response with tolerable side effects.

A common misconception: that you reach 2.4 mg, lose your target weight, and then stop the medication. The STEP 4 trial directly tested this. Participants who switched from semaglutide to placebo after 20 weeks regained two-thirds of their lost weight over the following 48 weeks. GLP-1 medications manage weight the way blood pressure medications manage blood pressure — stopping the medication typically means the condition returns.

Current clinical thinking leans toward:

• Indefinite maintenance at the lowest effective dose — some prescribers reduce from 2.4 mg to 1.0 mg or 1.7 mg once goal weight is achieved, finding the minimum dose that prevents significant regain.
• Lifestyle optimization during the active weight loss phase (resistance training, protein intake, behavioral habits) to improve the chances of maintaining weight if the medication is eventually reduced or stopped.
• Periodic dose holidays — some prescribers are experimenting with intermittent dosing (e.g., every other week at maintenance), though this is not yet supported by large trial data.

• Inject the evening before a day off — the first 24–48 hours after a dose increase tend to have the worst nausea. Sleeping through the peak helps.
• Eat a small, bland meal before injecting — having something in your stomach buffers the initial GI impact.
• Keep ginger chews or peppermint tea on hand — both are evidence-supported nausea remedies that many GLP-1 users swear by during dose transitions.
• Increase water intake — dehydration worsens every GI side effect. Aim for 80–100 oz per day, especially during dose increases.
• Track symptoms during the transition week — note which day post-injection is worst, what foods trigger nausea, and when symptoms resolve. This information is invaluable if you need to adjust the schedule with your prescriber.